Medpace Holdings Inc vs Target Corporation — how do they compare? Medpace Holdings Inc trades at $611.57 (market cap $16.82B), while Target Corporation trades at $153.77 (market cap $70.31B). The key difference: Target Corporation is far larger — about 4.2× Medpace Holdings Inc's market cap, and Target Corporation pays a 3% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and Target Corporation for 137 Days on average.
| MEDP | TGT | |
|---|---|---|
Market Cap | $16.82B | $70.31B |
Volume | 223,093 | 4,164,999 |
Sector | Health | Consumer Staples |
52-Week High | $630.19 | $169.90 |
52-Week Low | $393.42 | $83.68 |
Typical Hold Time | 14 Days | 137 Days |
Enterprise Value | $16.44B | $83.58B |
Dividend Yield | — | 3% |
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $612.05, up 1.29% today, near its consensus price target of $620.44. The stock shows strong profitability with a 17.67% net margin and has beaten earnings estimates for the last three quarters. Technical indicators are neutral overall, with support at $595 and resistance at $612. Recent news highlights CEO stock sales and institutional position changes, while the company prepares to report Q3 2026 results on October 21.
Outlook remains positive given consistent earnings beats and projected revenue growth to $2.8B in 2026. Risks include high valuation multiples (P/E 35.41) and insider selling. Analyst consensus is cautious with 79% hold ratings, suggesting limited near-term upside but solid fundamental support for long-term holders.
Target (TGT) trades at $153.77, up 1.86% today, with a bearish technical signal but strong fundamental support. The stock shows robust earnings beats in recent quarters, with Q2 2026 EPS of $4.11 significantly exceeding the $2.35 estimate. Valuation ratios like a P/E of 16.05 and P/S of 0.65 appear attractive relative to historical averages. Recent news highlights strategic price cuts on 2,000 items to boost holiday sales and market share.
The outlook is cautiously optimistic, supported by solid profitability, dividend reliability, and analyst consensus pointing to upside. Key risks include competitive pressures, margin compression from pricing strategies, and broader retail sector volatility. The consensus price target of $167.18 suggests potential appreciation, but investors should weigh execution risks against growth initiatives.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →With 1,926 stores (as of the end of fiscal 2021), Target is a leading American general merchandise retailer, offering a variety of products across several categories, including beauty and household essentials (26% of fiscal 2021 sales), food and beverage (19%), home furnishings and décor (19%), hardlines (18%), and apparel and accessories (17%). Most of Target's stores are large, averaging more than 125,000 square feet. The company has a significant e-commerce presence, deriving around 19% of sales from the channel (up from about 9% in fiscal 2019, before the pandemic). In addition to its namesake stores, Target owns Shipt, an online same-day delivery platform. After it exited Canada in 2015, virtually all of Target's revenue is generated from the United States.
Read more on TGT →